Merck's Cladribine Capsules Receive FDA Fast Track Designation for Rare Neuromuscular Disorder
核心洞察
Merck (搜索)'s cladribine capsules have received FDA Fast Track designation for treating generalized Myasthenia Gravis (搜索), potentially becoming the first oral treatment for this rare autoimmune neuromuscular disorder.
The drug previously received Orphan Drug Designation and is currently being evaluated in the global Phase 3 MyClad trial involving 264 patients with gMG (搜索).
Cladribine targets B and T cells (搜索) that produce harmful autoantibodies causing inflammation at the neuromuscular junction (搜索), offering a convenient oral regimen for patients.
Merck (搜索) announced that the U.S. Food and Drug Administration has granted Fast Track designation for cladribine capsules for the treatment of generalized Myasthenia Gravis (搜索) (gMG (搜索)), a rare chronic autoimmune neuromuscular disorder. The designation builds on the Orphan Drug Designation the FDA granted for cladribine capsules in June 2023.
If approved, cladribine capsules could become the first oral treatment for gMG (搜索), currently being studied in the global Phase 3 MyClad trial. The FDA's Fast Track program facilitates development and accelerates review of therapies for serious conditions with unmet medical needs, potentially bringing treatments to patients sooner.
"The FDA's Fast Track designation, together with Orphan Drug Designation, affirms that more treatments are needed for the gMG (搜索) community," said David Weinreich, MD, Global Head of R&D and Chief Medical Officer, Healthcare business of Merck (搜索). "As a patient-directed company, we are prioritizing the voices of MG patients in shaping our clinical program."
Patient-Centered Development Approach
Merck (搜索) has developed a patient council and collaborates with more than 20 MG patient advocacy groups around the world to shape the MyClad trial. Insights from the council have informed study protocols, recruitment materials and potential future product packaging options for the clinical trial program.
The company is also collaborating with Ad Scientiam, a medical equipment manufacturing company, to launch a prospective, multi-center pilot study exploring investigational software as a medical device designed to support gMG (搜索) management. The study will investigate how wearable technologies, smartphone-based functional tests, and electronic patient-reported outcomes could detect changes in disease trajectory in real-world conditions.
MyClad Phase 3 Trial Design
The MyClad trial (NCT06463587) is a global Phase 3, randomized, double-blind and placebo-controlled study designed to assess the efficacy and safety of cladribine capsules in 264 patients with gMG (搜索). Patients will be randomized to receive either two short courses of cladribine (low-dose or high-dose) or matched oral placebo, with courses separated by 4 weeks, followed by a blinded extension period and a retreatment period to assess sustained benefit, need for retreatment and long-term safety.
The primary endpoint is change from baseline in the MG-Activities of Daily Living (MG-ADL) score at Week 24 of the double-blind placebo-controlled period.
Mechanism of Action and Disease Impact
Cladribine is proposed to target selectively the B and T cells (搜索) believed to contribute to the production of harmful autoantibodies that cause inflammation and damage to the neuromuscular junction (搜索). This mechanism of action, combined with a short-course infrequently-administered oral regimen taken at home, may help reduce the burden of the disease by addressing its underlying cause if approved.
Generalized Myasthenia Gravis (搜索) is a rare, chronic autoimmune neuromuscular disorder characterized by muscle weakness and fatigue, impacting an estimated 700,000 people worldwide. The disease can strike anyone at any age but is more frequently seen in young women (age 20 to 30) and men aged 50 and older.
In gMG (搜索), communication between nerves and muscles, particularly at the neuromuscular junction (搜索), is disrupted causing muscle weakness. This can result in loss of control in the eye muscles and a variable combination of the arms, legs, and respiratory muscles. The unpredictable severity and frequency of symptoms in gMG patients can be debilitating, significantly impacting various aspects of day-to-day life.
Merck (搜索) will announce results from the MyClad trial following its completion and remains committed to ongoing collaboration with the gMG (搜索) community to ensure patient needs continue to guide clinical developments.